Wp. Farquhar-smith et Asc. Rice, Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder, ANESTHESIOL, 94(3), 2001, pp. 507-513
Citations number
39
Categorie Soggetti
Aneshtesia & Intensive Care","Medical Research Diagnosis & Treatment
Background: Referred hyperalgesia to a somatopically appropriate superficia
l site is a cardinal symptom of visceral inflammatory pain and has been dem
onstrated after turpentine-induced urinary bladder inflammation in the rat.
The authors examined the effect of the endocannabinoids anandamide and pal
mitoylethanolamide oil the referred hyperalgesia associated with this model
.
Methods After measurement of baseline limb withdrawal latencies to a noxiou
s heat stimulus, the bladders of 50 female Wistar rats mere inflamed by int
ravesical administration of 0.5 ml 50% turpentine. Ten or 25 mg/kg of anand
amide or palmitoylethanolamide or vehicle were administered immediately bef
ore introduction of turpentine, Antagonists to both the cannabinoid CB1 and
CB2 receptors mere coadministered with the higher dose of endocannabinoids
. Latencies were recorded 2, 4, 6, 8, and 24 h after removal of turpentine.
The difference between fore limb and hind limb withdrawal latencies was pl
otted against time, and areas under these curves were compared.
Results: Inflammation of the urinary bladder was associated with a relative
thermal hyperalgesia referred to the hind limb. Anandamide and palmitoylet
hanolamide attenuated this referred;hyperalgesia at doses of 10 and 25 mg/k
g, The CB, receptor antagonist SR141716A reduced the antihyperalgesic effec
t of anandamide, but the CB, antagonist SR144528 did not. Coadministration
of SR141716A with palmitoylethatlolamide did not affect the antihyperalgesi
c effect but was reduced by SR144528.
Conclusions: Anandamide (via CB1 receptors) and palmitoylethanolamide (puta
tively via CB, receptors) attenuated a referred hyperalgesia in a dose-depe
ndent fashion. CB, and CB, receptors are strategically situated to influenc
e the nerve growth factor-driven referred hyperalgesia associated with infl
ammation of the urinary bladder. These data implicate cannabinoids as a nov
el treatment for vesical pain,